Acurx Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.3M | $-1.7M | $-1.6M | $-2.0M | $-2.2M | $-2.1M | $-2.8M | $-2.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $200.5K | $258.3K | $294.8K | $294.8K | $324.2K | $333.6K | $345.2K | $345.2K |
| Net Cash from Operating Activities | $-1.7M | $-1.4M | $-1.2M | $-1.9M | $-1.7M | $-2.1M | $-2.3M | $-2.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.1M | $3.1M | $2.8M | $1.7M | $3.1M | $3.0M | $194.5K | $1.6M |
| Net Change in Cash | $1.4M | $1.7M | $1.6M | $-157.3K | $1.4M | $937.2K | $-2.1M | $-598.3K |
| Free Cash Flow | — | — | — | — | — | — | — | — |